U.S. Markets open in 4 hrs 11 mins

Amgen Inc. (AMGN)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
173.67+1.17 (+0.68%)
At close: 4:00PM EDT
People also watch
BIIBGILDCELGMRKBMY
Full screen
Previous Close172.50
Open173.39
Bid171.40 x 300
Ask176.05 x 300
Day's Range172.41 - 174.72
52 Week Range133.64 - 184.21
Volume3,037,563
Avg. Volume3,504,318
Market Cap127.72B
Beta1.76
PE Ratio (TTM)16.50
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield4.60 (2.67%)
Ex-Dividend Date2017-05-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters4 hours ago

    Novartis gets European OK for biosimilar of Amgen's Enbrel

    Novartis's generics unit Sandoz said the European Commission approved Erelzi, its biosimilar to Amgen's Enbrel, to treat inflammatory diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis. The approval was based on a development programme that demonstrated that Erelzi, a biosimilar of the drug also known as etanercept, matches its reference medicine in terms of safety, efficacy, and quality, Sandoz said in a statement on Tuesday.

  • Barrons.com18 hours ago

    Regeneron: The End of the Outperformance?

    Regeneron Pharmaceuticals (REGN) has been hot this year, so hot in fact that I recommended buying its shares in May, while Jack Hough this month reiterated his bullish call from more than a year ago. Regeneron has benefited from a positive ruling in its patent battle against Amgen (AMGN), and the launch of Dupixent.

  • Benzinga4 days ago

    Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold

    Biotech stocks have been on a tear in the past week, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) up 8.8 percent. However, despite the run-up, Deutsche Bank sees more upside ahead for ...